Nanomedicine-based therapeutic strategies for cerebral ischemia-reperfusion injury: from blood-brain barrier penetration to precision targeting.

IF 4.8 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Xiaomeng Guo, Guohao Liu, Yong Liu, Meiling Jin, Zihao Yong, Fukai Li, Shicheng Tang, Liwei Xie, Chunming Huang, Qingchun Mu, He Bai
{"title":"Nanomedicine-based therapeutic strategies for cerebral ischemia-reperfusion injury: from blood-brain barrier penetration to precision targeting.","authors":"Xiaomeng Guo, Guohao Liu, Yong Liu, Meiling Jin, Zihao Yong, Fukai Li, Shicheng Tang, Liwei Xie, Chunming Huang, Qingchun Mu, He Bai","doi":"10.1186/s40001-026-04073-w","DOIUrl":null,"url":null,"abstract":"<p><p>Cerebral ischemia-reperfusion injury (CIRI) represents a major contributing factor to adverse outcomes following ischemic stroke (IS), posing significant challenges to patient survival and long-term quality of life. Although various anti-inflammatory and antioxidant agents are currently employed clinically for CIRI treatment, their therapeutic efficacy remains constrained by blood-brain barrier (BBB) limitations and inherent drug limitations, including poor pharmacokinetics and limited in vivo stability. In recent years, nanotechnology has gained increasing prominence in the medical field, with rationally designed nanomedicines demonstrating enhanced BBB permeability and improved bioavailability, emerging as a promising therapeutic approach for CIRI. This review provides a concise overview of the pathological mechanisms underlying CIRI, highlights recent advances in various nanomedicines carrier systems, explores multiple delivery strategies ranging from passive diffusion to active targeting across the BBB, and discusses cutting-edge therapeutic approaches for precision targeting of specific organelles and cellular compartments, with the aim of providing novel insights for subsequent CIRI delivery strategies and therapeutic targets.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40001-026-04073-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Cerebral ischemia-reperfusion injury (CIRI) represents a major contributing factor to adverse outcomes following ischemic stroke (IS), posing significant challenges to patient survival and long-term quality of life. Although various anti-inflammatory and antioxidant agents are currently employed clinically for CIRI treatment, their therapeutic efficacy remains constrained by blood-brain barrier (BBB) limitations and inherent drug limitations, including poor pharmacokinetics and limited in vivo stability. In recent years, nanotechnology has gained increasing prominence in the medical field, with rationally designed nanomedicines demonstrating enhanced BBB permeability and improved bioavailability, emerging as a promising therapeutic approach for CIRI. This review provides a concise overview of the pathological mechanisms underlying CIRI, highlights recent advances in various nanomedicines carrier systems, explores multiple delivery strategies ranging from passive diffusion to active targeting across the BBB, and discusses cutting-edge therapeutic approaches for precision targeting of specific organelles and cellular compartments, with the aim of providing novel insights for subsequent CIRI delivery strategies and therapeutic targets.

基于纳米药物的脑缺血再灌注损伤治疗策略:从血脑屏障渗透到精确靶向。
脑缺血再灌注损伤(CIRI)是缺血性卒中(IS)后不良结局的主要影响因素,对患者的生存和长期生活质量构成重大挑战。尽管目前临床应用了多种抗炎和抗氧化剂治疗CIRI,但其治疗效果仍然受到血脑屏障(BBB)局限性和固有药物局限性的限制,包括药代动力学差和体内稳定性有限。近年来,纳米技术在医学领域的应用日益突出,合理设计的纳米药物可以增强血脑屏障的通透性,提高生物利用度,成为治疗CIRI的一种很有前景的方法。本文简要介绍了CIRI的病理机制,重点介绍了各种纳米药物载体系统的最新进展,探讨了从被动扩散到主动靶向的多种传递策略,并讨论了精确靶向特定细胞器和细胞室的尖端治疗方法,旨在为后续CIRI传递策略和治疗靶点提供新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Journal of Medical Research
European Journal of Medical Research 医学-医学:研究与实验
CiteScore
3.20
自引率
0.00%
发文量
247
审稿时长
>12 weeks
期刊介绍: European Journal of Medical Research publishes translational and clinical research of international interest across all medical disciplines, enabling clinicians and other researchers to learn about developments and innovations within these disciplines and across the boundaries between disciplines. The journal publishes high quality research and reviews and aims to ensure that the results of all well-conducted research are published, regardless of their outcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书